AIM ImmunoTech Files Three Provisional Patent Applications Surrounding Ampligen(R) for Use Against the SARS-like Wuhan 2019 Novel Coronavirus
AIM ImmunoTech Inc. (NYSE American:AIM) announced the filing of three provisional patent applications related to its drug candidate Ampligen in the company’s efforts toward joining the global health community in the fight against the deadly Wuhan coronavirus that has so far infected approximately 40,000 people and killed almost one thousand, primarily in China. Coronaviruses are a large family of viruses, including the deadly Severe Acute Respiratory Syndrome (SARS). After a 2002 SARS outbreak in the Guangdong province of southern China…